ClinicalTrials.gov record
Terminated Phase 2 Interventional

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

ClinicalTrials.gov ID: NCT05512377

Public ClinicalTrials.gov record NCT05512377. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

Study identification

NCT ID
NCT05512377
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
99 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 12, 2022
Primary completion
Sep 24, 2025
Completion
Sep 24, 2025
Last update posted
May 13, 2026

2022 – 2025

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Southern Cancer Center Mobile Alabama 36608
University of Arizona Tucson Arizona 85719
University of Southern California Los Angeles California 90033-9173
Stanford Cancer Institute Palo Alto California 94305
Providence Medical Foundation-Santa Rosa -69764 Santa Rosa California 95403
Rocky Mountain Cancer Centers-Lone Tree-69498 Lone Tree Colorado 80124
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Washington D.C. District of Columbia 20016
Norton Cancer Institute, Downtown Louisville Kentucky 40202
University of Michigan Ann Arbor Michigan 48109
Nebraska Cancer Specialists-Omaha-69066 Omaha Nebraska 68130
Perlmutter Cancer Center at NYU Langone Hospital - Long Island Mineola New York 11501
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health New York New York 10016
Memorial Sloan-Kettering Cancer Center New York New York 10022
Cleveland Clinic Cleveland Ohio 44195
Oncology Associates of Oregon, PC Eugene Oregon 97401
Oregon Health and Sciences University Portland Oregon 97239
University of Pennsylvania Philadelphia Pennsylvania 19104
The University of Texas MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05512377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05512377 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →